Latest Articles

Publication Date
All News Scientific
Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer - OncLive

Dr O'Cearbhaill on the Evaluation of REGN5668 in Recurrent Ovarian or Endometrial Cancer OncLive

Published: April 12, 2026, 12:58 a.m.
Read Full Article
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive

Published: April 11, 2026, 4:04 p.m.
Read Full Article
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

Published: April 11, 2026, 11:01 a.m.
Read Full Article
In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan

Published: April 11, 2026, 11 a.m.
Read Full Article
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer epi-phare

Published: March 9, 2026, 10:32 a.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.
Read Full Article
Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Yahoo Finance Singapore

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Yahoo …

Published: Feb. 3, 2026, 1 p.m.
Read Full Article
Novel Vaccine Combo Shows Responses in Recurrent Epithelial Ovarian Cancer - CancerNetwork

Novel Vaccine Combo Shows Responses in Recurrent Epithelial Ovarian Cancer CancerNetwork

Published: Jan. 21, 2026, 4:57 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!